Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors

Fig. 3

CBL0137 treatment downregulates HR genes in HGSCs. A Mean-difference plot for differential expression analysis between CBL0137-treated and vehicle control DF149 HGSC cells. Significantly upregulated and downregulated genes are colored red and blue, respectively. Significance based on FDR < 0.05. B Dot plot of the top 10 results from Reactome pathway analysis using the significantly downregulated genes (logFC < 0 and FDR < 0.05) in CBL0137-treated samples. C Heatmap of the significantly downregulated genes contributing to Reactome Pathway “DNA Repair” (R-HSA-73894). The genes with logFC < 0 and FDR < 0.05 from differential expression analysis of CBL0137-treated vs. vehicle control were used as input to Reactome. D Gene Set Enrichment Analysis showing MYC target V2 gene signature are enriched in DF149 cells upon DMSO treatment. E OVCAR-8, OVCAR-4, and DF149 cells were treated with 1 μM of CBL0137, for indicated time period. The mRNA expression of indicated genes was evaluated by RT-qPCR (n = 3). Statistical significance was determined by Unpaired Student’s t-tests

Back to article page